{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T17:01:50Z","timestamp":1784480510577,"version":"3.55.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:00:00Z","timestamp":1784419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Biomed Eng"],"DOI":"10.1007\/s10439-026-04282-8","type":"journal-article","created":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T14:38:55Z","timestamp":1784471935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Spatiotemporal Image-Guided Model of Radiopharmaceutical Transport in Heterogeneous Vasculature Prostate Tumor: A Computational Analysis of Key Parameters in Lutetium-177 PSMA Therapy"],"prefix":"10.1007","author":[{"given":"Zahra","family":"Raziei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saptarshi","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arman","family":"Rahmim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,19]]},"reference":[{"issue":"3","key":"4282_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.3390\/ph17030351","volume":"17","author":"A Bernal","year":"2024","unstructured":"Bernal, A., A. J. Bechler, K. Mohan, A. Rizzino, and G. Mathew. The current therapeutic landscape for metastatic prostate cancer. Pharmaceuticals. 17(3):351, 2024.","journal-title":"Pharmaceuticals"},{"key":"4282_CR2","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.jconrel.2024.05.004","volume":"370","author":"A Bhandari","year":"2024","unstructured":"Bhandari, A., B. Gu, F. M. Kashkooli, and W. Zhan. Image-based predictive modelling frameworks for personalised drug delivery in cancer therapy. J. Controlled Release. 370:721\u2013746, 2024.","journal-title":"J. Controlled Release"},{"issue":"6","key":"4282_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020344","volume":"6","author":"M Soltani","year":"2011","unstructured":"Soltani, M., and P. Chen. Numerical modeling of fluid flow in solid tumors. PloS One.6(6):e20344, 2011.","journal-title":"PloS One."},{"key":"4282_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jconrel.2021.11.024","volume":"341","author":"M Souri","year":"2022","unstructured":"Souri, M., M. Soltani, F. M. Kashkooli, and M. K. Shahvandi. Engineered strategies to enhance tumor penetration of drug-loaded nanoparticles. J. Controlled Release. 341:227\u2013246, 2022.","journal-title":"J. Controlled Release"},{"issue":"4","key":"4282_CR5","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.3390\/ijms23042127","volume":"23","author":"CY Li","year":"2022","unstructured":"Li, C. Y., S. Brown, B. J. Mehrara, and R. P. Kataru. Lymphatics in tumor progression and immunomodulation. Int. J. Mol. Sci. 23(4):2127, 2022.","journal-title":"Int. J. Mol. Sci."},{"issue":"6382","key":"4282_CR6","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1126\/science.aal3622","volume":"359","author":"ER Pereira","year":"2018","unstructured":"Pereira, E. R., D. Kedrin, G. Seano, O. Gautier, E. F. Meijer, D. Jones, et al. Lymph node metastases can invade local blood vessels, exit the node, and colonize distant organs in mice. Science. 359(6382):1403\u20131407, 2018.","journal-title":"Science."},{"issue":"10","key":"4282_CR7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"C-H Heldin","year":"2004","unstructured":"Heldin, C.-H., K. Rubin, K. Pietras, and A. \u00d6stman. High interstitial fluid pressure\u2014an obstacle in cancer therapy. Nat. Rev. Cancer. 4(10):806\u2013813, 2004.","journal-title":"Nat. Rev. Cancer."},{"issue":"1","key":"4282_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40658-024-00700-9","volume":"11","author":"C Miller","year":"2024","unstructured":"Miller, C., I. Klyuzhin, G. Chauss\u00e9, J. Brosch-Lenz, H. Koniar, K. Shi, et al. Impact of cell geometry, cellular uptake region, and tumour morphology on 225Ac and 177Lu dose distributions in prostate cancer. EJNMMI Phys. 11(1):1\u201319, 2024.","journal-title":"EJNMMI Phys."},{"issue":"4","key":"4282_CR9","first-page":"e58842","volume":"16","author":"TA Waraich","year":"2024","unstructured":"Waraich, T. A., S. Y. Khalid, U. M. Kathia, A. Ali, S. S. S. Qamar, A. Yousuf, et al. Assessing the efficacy and long-term outcomes of surgical intervention versus radiotherapy: a comprehensive systematic review and meta-analysis of prostate cancer treatment modalities. Cureus. 16(4):e58842, 2024.","journal-title":"Cureus."},{"issue":"2","key":"4282_CR10","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/cancers15020461","volume":"15","author":"P Posdzich","year":"2023","unstructured":"Posdzich, P., C. Darr, T. Hilser, M. Wahl, K. Herrmann, B. Hadaschik, et al. Metastatic prostate cancer\u2014a review of current treatment options and promising new approaches. Cancers. 15(2):461, 2023.","journal-title":"Cancers."},{"issue":"18","key":"4282_CR11","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.3390\/cancers16183120","volume":"16","author":"H Abdollahi","year":"2024","unstructured":"Abdollahi, H., A. Fele-Paranj, and A. Rahmim. Model-informed radiopharmaceutical therapy optimization: a study on the impact of pbpk model parameters on physical, biological, and statistical measures in 177Lu-PSMA therapy. Cancers. 16(18):3120, 2024.","journal-title":"Cancers."},{"issue":"1","key":"4282_CR12","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1038\/s41540-024-00467-w","volume":"10","author":"M Souri","year":"2024","unstructured":"Souri, M., S. Elahi, F. Moradi Kashkooli, M. Kohandel, and M. Soltani. Enhancing localized chemotherapy with anti-angiogenesis and nanomedicine synergy for improved tumor penetration in well-vascularized tumors. Npj Syst. Biol. Appl. 10(1):136, 2024.","journal-title":"Npj Syst. Biol. Appl."},{"issue":"3","key":"4282_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3390\/receptors3030016","volume":"3","author":"A Prajapati","year":"2024","unstructured":"Prajapati, A., S. Rangra, R. Patil, N. Desai, V. G. S. Jyothi, S. Salave, et al. Receptor-targeted nanomedicine for cancer therapy. Receptors. 3(3):323\u2013361, 2024.","journal-title":"Receptors."},{"issue":"3","key":"4282_CR14","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/targets2030011","volume":"2","author":"X Chen","year":"2024","unstructured":"Chen, X., D. Wang, Y.-B. Jiang, and T. Jiang. Design of cell-specific targeting peptides for cancer therapy. Targets. 2(3):186\u2013201, 2024.","journal-title":"Targets."},{"key":"4282_CR15","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3389\/fphys.2019.00096","volume":"10","author":"Z Wang","year":"2019","unstructured":"Wang, Z., and T. S. Deisboeck. Dynamic targeting in cancer treatment. Front. Physiol. 10:96, 2019.","journal-title":"Front. Physiol."},{"issue":"17","key":"4282_CR16","first-page":"1642","volume":"327","author":"HD Larkin","year":"2022","unstructured":"Larkin, H. D. Targeted radioligand approved for metastatic prostate cancer. JAMA. 327(17):1642, 2022.","journal-title":"JAMA."},{"issue":"5","key":"4282_CR17","doi-asserted-by":"publisher","DOI":"10.1088\/2057-1976\/ace44a","volume":"9","author":"M Galler","year":"2023","unstructured":"Galler, M., C. Chibolela, J. Rogasch, K. Huang, J. Siefert, I. Schatka, et al. Dosimetric analysis of a compartmental model for radioligand uptake in tumor lesions. Biomed. Phys. Eng. Exp.9(5):055005, 2023.","journal-title":"Biomed. Phys. Eng. Exp."},{"issue":"9","key":"4282_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","volume":"19","author":"G Sgouros","year":"2020","unstructured":"Sgouros, G., L. Bodei, M. R. McDevitt, and J. R. Nedrow. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat. Rev. Drug Discov. 19(9):589\u2013608, 2020.","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"4282_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41420-023-01778-3","volume":"10","author":"T Zhang","year":"2024","unstructured":"Zhang, T., H. Lei, X. Chen, Z. Dou, B. Yu, W. Su, et al. Carrier systems of radiopharmaceuticals and the application in cancer therapy. Cell Death Discov. 10(1):16, 2024.","journal-title":"Cell Death Discov."},{"issue":"5","key":"4282_CR20","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/oncolo\/oyac279","volume":"28","author":"B Ramnaraign","year":"2023","unstructured":"Ramnaraign, B., and O. Sartor. PSMA-targeted radiopharmaceuticals in prostate cancer: current data and new trials. The Oncol. 28(5):392\u2013401, 2023.","journal-title":"The Oncol."},{"issue":"12","key":"4282_CR21","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.3390\/biomedicines10123020","volume":"10","author":"S van der Gaag","year":"2022","unstructured":"van der Gaag, S., I. H. Bartelink, A. N. Vis, G. L. Burchell, D. E. Oprea-Lager, and H. Hendrikse. Pharmacological optimization of PSMA-based radioligand therapy. Biomedicines. 10(12):3020, 2022.","journal-title":"Biomedicines."},{"issue":"12","key":"4282_CR22","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.3390\/pharmaceutics15122761","volume":"15","author":"Y Khazaei Monfared","year":"2023","unstructured":"Khazaei Monfared, Y., P. Heidari, S. J. Klempner, U. Mahmood, A. R. Parikh, T. S. Hong, et al. DNA damage by radiopharmaceuticals and mechanisms of cellular repair. Pharmaceutics. 15(12):2761, 2023.","journal-title":"Pharmaceutics."},{"issue":"9","key":"4282_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41585-025-01014-w","volume":"2","author":"C Boixareu","year":"2025","unstructured":"Boixareu, C., T. Taha, V. B. Venkadakrishnan, J. de Bono, and H. Beltran. Targeting the tumour cell surface in advanced prostate cancer. Nat. Rev. Urol. 2(9):569\u2013589, 2025.","journal-title":"Nat. Rev. Urol."},{"issue":"16","key":"4282_CR24","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.3390\/cancers13163967","volume":"13","author":"M El Fakiri","year":"2021","unstructured":"El Fakiri, M., N. M. Geis, N. Ayada, M. Eder, and A.-C. Eder. PSMA-targeting radiopharmaceuticals for prostate cancer therapy: recent developments and future perspectives. Cancers. 13(16):3967, 2021.","journal-title":"Cancers."},{"issue":"18","key":"4282_CR25","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.3390\/cancers15184537","volume":"15","author":"M Abusalem","year":"2023","unstructured":"Abusalem, M., L. Martiniova, S. Soebianto, L. DePalatis, and G. Ravizzini. Current status of radiolabeled monoclonal antibodies targeting PSMA for imaging and therapy. Cancers. 15(18):4537, 2023.","journal-title":"Cancers."},{"issue":"5","key":"4282_CR26","doi-asserted-by":"publisher","first-page":"4741","DOI":"10.3390\/ijms24054741","volume":"24","author":"J Moon","year":"2023","unstructured":"Moon, J., I. Kitty, K. Renata, S. Qin, F. Zhao, and W. Kim. DNA damage and its role in cancer therapeutics. Int. J. Mol. Sci. 24(5):4741, 2023.","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"4282_CR27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.2174\/1874471008666150313114644","volume":"9","author":"T Das","year":"2016","unstructured":"Das, T., and S. Banerjee. Theranostic applications of lutetium-177 in radionuclide therapy. Curr. Radiopharm. 9(1):94\u2013101, 2016.","journal-title":"Curr. Radiopharm."},{"key":"4282_CR28","unstructured":"Bhardwaj R. Radionuclide generator based production of therapeutic lutetium-177. 2019."},{"key":"4282_CR29","doi-asserted-by":"publisher","first-page":"1239118","DOI":"10.3389\/fonc.2023.1239118","volume":"13","author":"P Szponar","year":"2023","unstructured":"Szponar, P., P. Petrasz, K. Brze\u017aniakiewicz-Janus, T. Drewa, P. Zorga, and J. Adamowicz. Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer\u2013a narrative review. Front. Oncol. 13:1239118, 2023.","journal-title":"Front. Oncol."},{"issue":"1","key":"4282_CR30","doi-asserted-by":"publisher","first-page":"20041","DOI":"10.1038\/s41598-019-56603-8","volume":"9","author":"NJ Begum","year":"2019","unstructured":"Begum, N. J., G. Glatting, H.-J. Wester, M. Eiber, A. J. Beer, and P. Kletting. The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: a simulation study using a PBPK model. Sci. Rep. 9(1):20041, 2019.","journal-title":"Sci. Rep."},{"issue":"1","key":"4282_CR31","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s12672-024-01680-z","volume":"15","author":"A Konopnicki","year":"2024","unstructured":"Konopnicki, A., M. Zaliznyak, M. Roy, and B. Jana. The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials. Discov. Oncol. 15(1):791, 2024.","journal-title":"Discov. Oncol."},{"issue":"2","key":"4282_CR32","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/RLU.0000000000005000","volume":"49","author":"S Satapathy","year":"2024","unstructured":"Satapathy, S., M. P. Yadav, S. Ballal, R. K. Sahoo, and C. Bal. Promising therapeutic activity of 177Lu-PSMA-617 in synchronous high-volume metastatic hormone-sensitive prostate cancer: a pilot experience. Clin. Nuclear Med. 49(2):131\u2013137, 2024.","journal-title":"Clin. Nuclear Med."},{"issue":"11","key":"4282_CR33","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","volume":"24","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal, R., S. Starzinski, I. de Kouchkovsky, V. Koshkin, R. Bose, J. Chou, et al. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 24(11):1266\u20131276, 2023.","journal-title":"Lancet Oncol."},{"issue":"3","key":"4282_CR34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3390\/biomedicines13030569","volume":"13","author":"E Kalender","year":"2025","unstructured":"Kalender, E., E. Ekinci, U. Elbo\u011fa, and E. \u015eahin. Efficacy of 177Lu-PSMA-617 therapy in mCRPC patients with liver metastases: insights into survival outcomes and predictors of response. Biomedicines. 13(3):569, 2025.","journal-title":"Biomedicines."},{"key":"4282_CR35","volume-title":"Prostate cancer theranostics with 177Lu-PSMA. Seminars in nuclear medicine","author":"H Ahmadzadehfar","year":"2024","unstructured":"Ahmadzadehfar, H., R. Seifert, A. Afshar-Oromieh, C. Kratochwil, and K. Rahbar. Prostate cancer theranostics with 177Lu-PSMA. Seminars in nuclear medicine. Amsterdam: Elsevier, 2024."},{"issue":"5","key":"4282_CR36","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/pharmaceutics13050674","volume":"13","author":"TS Damiana","year":"2021","unstructured":"Damiana, T. S., and S. U. Dalm. Combination therapy, a promising approach to enhance the efficacy of radionuclide and targeted radionuclide therapy of prostate and breast cancer. Pharmaceutics. 13(5):674, 2021.","journal-title":"Pharmaceutics."},{"issue":"8","key":"4282_CR37","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1021\/acs.molpharmaceut.9b00250","volume":"16","author":"G Gocheva","year":"2019","unstructured":"Gocheva, G., and A. Ivanova. A look at receptor\u2013ligand pairs for active-targeting drug delivery from crystallographic and molecular dynamics perspectives. Molecular Pharm. 16(8):3293\u20133321, 2019.","journal-title":"Molecular Pharm."},{"key":"4282_CR38","unstructured":"Rezaeian, M., Soltani, M., Moradi Kashkooli, editors. On the modeling of drug delivery to solid tumors; computational viewpoint. International Conference on Applied Mathematics, Modeling and Computational Science. Berlin; Springer, 2019"},{"key":"4282_CR39","first-page":"242405","volume":"65","author":"E Mollaheydar","year":"2024","unstructured":"Mollaheydar, E., H. S. Ahn, B. Saboury, A. Rahmim, and E. Cytrynbaum. Spatiotemporal kinetic modeling of radiopharmaceutical therapies at cellular resolution in heterogeneous tumors. Soc. Nuclear Med. 65:242405, 2024.","journal-title":"Soc. Nuclear Med."},{"key":"4282_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07084-w","volume":"20","author":"S Casarin","year":"2020","unstructured":"Casarin, S., and E. Dondossola. An agent-based model of prostate Cancer bone metastasis progression and response to Radium223. BMC cancer. 20:1\u201319, 2020.","journal-title":"BMC cancer."},{"key":"4282_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmp.2024.103299","volume":"119","author":"V Vasi\u0107","year":"2024","unstructured":"Vasi\u0107, V., J. Gustafsson, E. Y. Nowshahr, A. Stenvall, A. J. Beer, K. S. Gleisner, et al. A PBPK model for PRRT with [177Lu] Lu-DOTA-TATE: Comparison of model implementations in SAAM II and MATLAB\/SimBiology. Physica Medica.119:103299, 2024.","journal-title":"Physica Medica."},{"key":"4282_CR42","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cpet.2025.09.004","volume":"21","author":"D Hardiansyah","year":"2026","unstructured":"Hardiansyah, D., B. B. Patrianesha, K. Shi, B. Saboury, A. Rahmim, and G. Glatting. An overview of physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) models: applications to radiopharmaceutical therapies for analysis and personalization. PET Clinics. 21:89\u2013100, 2026.","journal-title":"PET Clinics."},{"issue":"2","key":"4282_CR43","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/mp.14622","volume":"48","author":"D Hardiansyah","year":"2021","unstructured":"Hardiansyah, D., P. Kletting, N. J. Begum, M. Eiber, A. J. Beer, S. A. Pawiro, et al. Important pharmacokinetic parameters for individualization of 177Lu-PSMA therapy: a global sensitivity analysis for a physiologically-based pharmacokinetic model. Med. Phys. 48(2):556\u2013568, 2021.","journal-title":"Med. Phys."},{"issue":"1","key":"4282_CR44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41181-023-00236-w","volume":"9","author":"A Fele-Paranj","year":"2024","unstructured":"Fele-Paranj, A., B. Saboury, C. Uribe, and A. Rahmim. Physiologically based radiopharmacokinetic (PBRPK) modeling to simulate and analyze radiopharmaceutical therapies: studies of non-linearities, multi-bolus injections, and albumin binding. EJNMMI Radiopharm. Chem. 9(1):6, 2024.","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"9","key":"4282_CR45","doi-asserted-by":"publisher","first-page":"5708","DOI":"10.1118\/1.4747266","volume":"39","author":"P Kletting","year":"2012","unstructured":"Kletting, P., B. M\u00fcller, B. Erentok, J. Schmaljohann, F. F. Behrendt, S. N. Reske, et al. Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. Med. Phys. 39(9):5708\u20135717, 2012.","journal-title":"Med. Phys."},{"issue":"9","key":"4282_CR46","doi-asserted-by":"publisher","first-page":"e0162303","DOI":"10.1371\/journal.pone.0162303","volume":"11","author":"P Kletting","year":"2016","unstructured":"Kletting, P., C. Schuchardt, H. R. Kulkarni, M. Shahinfar, A. Singh, G. Glatting, et al. Investigating the effect of ligand amount and injected therapeutic activity: a simulation study for 177Lu-labeled PSMA-targeting peptides. PLoS One. 11(9):e0162303, 2016.","journal-title":"PLoS One."},{"key":"4282_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2023.108004","volume":"245","author":"A Piranfar","year":"2024","unstructured":"Piranfar, A., M. Soltani, F. M. Kashkooli, C. F. Uribe, and A. Rahmim. Spatiotemporal modeling of radiopharmaceutical transport in solid tumors: application to 177Lu-PSMA therapy of prostate cancer. Comput. Methods Prog. Biomed.245:108004, 2024.","journal-title":"Comput. Methods Prog. Biomed."},{"issue":"1","key":"4282_CR48","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2967\/jnumed.124.268457","volume":"66","author":"NR Zaid","year":"2025","unstructured":"Zaid, N. R., R. Bastiaannet, R. Hobbs, and G. Sgouros. Mathematic modeling of tumor growth during [177Lu] Lu-PSMA therapy: insights into treatment optimization. J. Nuclear Med. 66(1):84\u201390, 2025.","journal-title":"J. Nuclear Med."},{"key":"4282_CR49","doi-asserted-by":"crossref","unstructured":"Soltani, M., Sefidgar, M., Casey, M., Wahl, R., Subramaniam, R., Rahmim, A., editors. Comprehensive modeling of the spatiotemporal distribution of PET tracer uptake in solid tumors based on the Convection-Diffusion-Reaction equation. 2014 IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS\/MIC); 2014: IEEE.","DOI":"10.1109\/NSSMIC.2014.7430813"},{"key":"4282_CR50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.mvr.2015.02.007","volume":"99","author":"M Sefidgar","year":"2015","unstructured":"Sefidgar, M., M. Soltani, K. Raahemifar, M. Sadeghi, H. Bazmara, M. Bazargan, et al. Numerical modeling of drug delivery in a dynamic solid tumor microvasculature. Microvasc. Res. 99:43\u201356, 2015.","journal-title":"Microvasc. Res."},{"key":"4282_CR51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s12149-016-1141-4","volume":"31","author":"M Soltani","year":"2017","unstructured":"Soltani, M., M. Sefidgar, H. Bazmara, M. E. Casey, R. M. Subramaniam, R. L. Wahl, et al. Spatiotemporal distribution modeling of PET tracer uptake in solid tumors. Ann. Nuclear Med. 31:109\u2013124, 2017.","journal-title":"Ann. Nuclear Med."},{"key":"4282_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2020.105399","volume":"151","author":"FM Kashkooli","year":"2020","unstructured":"Kashkooli, F. M., M. Soltani, and M.-H. Hamedi. Drug delivery to solid tumors with heterogeneous microvascular networks: Novel insights from image-based numerical modeling. Eur. J. Pharm. Sci.151:105399, 2020.","journal-title":"Eur. J. Pharm. Sci."},{"issue":"12","key":"4282_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189802","volume":"12","author":"C-Y Chou","year":"2017","unstructured":"Chou, C.-Y., W.-I. Chang, T.-L. Horng, and W.-L. Lin. Numerical modeling of nanodrug distribution in tumors with heterogeneous vasculature. Plos One.12(12):e0189802, 2017.","journal-title":"Plos One."},{"issue":"3","key":"4282_CR54","doi-asserted-by":"publisher","DOI":"10.1088\/2057-1976\/ab7a53","volume":"6","author":"P Shojaee","year":"2020","unstructured":"Shojaee, P., L. Alinezhad, and M. Sefidgar. Spatio-temporal investigation of doxorubicin in a 3D heterogeneous tumor microenvironment. Biomed. Phys. Eng. Exp.6(3):035008, 2020.","journal-title":"Biomed. Phys. Eng. Exp."},{"issue":"1","key":"4282_CR55","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41540-024-00362-4","volume":"10","author":"A Piranfar","year":"2024","unstructured":"Piranfar, A., F. Moradi Kashkooli, W. Zhan, A. Bhandari, B. Saboury, A. Rahmim, et al. Radiopharmaceutical transport in solid tumors via a 3-dimensional image-based spatiotemporal model. Npj Syst. Biol. Appl. 10(1):39, 2024.","journal-title":"Npj Syst. Biol. Appl."},{"key":"4282_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.655781","volume":"11","author":"F Moradi Kashkooli","year":"2021","unstructured":"Moradi Kashkooli, F., M. Soltani, M. M. Momeni, and A. Rahmim. Enhanced drug delivery to solid tumors via drug-loaded nanocarriers: an image-based computational framework. Front. Oncol.11:655781, 2021.","journal-title":"Front. Oncol."},{"key":"4282_CR57","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.mvr.2019.01.005","volume":"123","author":"FM Kashkooli","year":"2019","unstructured":"Kashkooli, F. M., M. Soltani, M. Rezaeian, E. Taatizadeh, and M.-H. Hamedi. Image-based spatio-temporal model of drug delivery in a heterogeneous vasculature of a solid tumor\u2014computational approach. Microvasc. Res. 123:111\u2013124, 2019.","journal-title":"Microvasc. Res."},{"issue":"1","key":"4282_CR58","doi-asserted-by":"publisher","first-page":"4052","DOI":"10.1038\/s41598-025-86159-9","volume":"15","author":"A Golzaryan","year":"2025","unstructured":"Golzaryan, A., M. Soltani, F. Moradi Kashkooli, B. Saboury, and A. Rahmim. Personalized metronomic radiopharmaceutical therapy through injection profile optimization via physiologically based pharmacokinetic (PBPK) modeling. Sci. Rep. 15(1):4052, 2025.","journal-title":"Sci. Rep."},{"key":"4282_CR59","doi-asserted-by":"crossref","unstructured":"Abdollahi, H., Fele-Paranj, A., Saboury, B., Uribe, C., Rahmim, A. editors. Radiobiological-guided radiopharmaceutical therapy: radiopharmacokinetic parameter optimization using PBPK modeling. 2023 IEEE Nuclear Science Symposium, Medical Imaging Conference and International Symposium on Room-Temperature Semiconductor Detectors (NSS MIC RTSD); IEEE, 2023.","DOI":"10.1109\/NSSMICRTSD49126.2023.10338502"},{"issue":"1","key":"4282_CR60","first-page":"41","volume":"37","author":"NR Zaid","year":"2022","unstructured":"Zaid, N. R., P. Kletting, G. Winter, A. J. Beer, and G. Glatting. A whole-body physiologically based pharmacokinetic model for alpha particle emitting bismuth in rats. Cancer Biother. Radiopharm. 37(1):41\u201346, 2022.","journal-title":"Cancer Biother. Radiopharm."},{"key":"4282_CR61","first-page":"77","volume":"48","author":"D Hardiansyah","year":"2021","unstructured":"Hardiansyah, D., A. Riana, P. Kletting, A. Beer, and G. Glatting. Simplified dosimetry for peptide-receptor radionuclide therapy using physiologically-based pharmacokinetic and nonlinear mixed effect modelling. Eur. J. Nuclear Med. Molecular Imaging. 48:77, 2021.","journal-title":"Eur. J. Nuclear Med. Molecular Imaging"},{"key":"4282_CR62","first-page":"392","volume":"49","author":"A Golzaryan","year":"2022","unstructured":"Golzaryan, A., M. Soltani, F. M. Kashkooli, B. Saboury, and A. Rahmim. Impact of metronomic radiopharmaceutical therapy on tumor and organ-at-risk absorbed doses: a PBPK modeling approach. Eur. J. Nuclear Med. Molecular Imaging. 49:392, 2022.","journal-title":"Eur. J. Nuclear Med. Molecular Imaging."},{"issue":"12","key":"4282_CR63","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor, O., J. De Bono, K. N. Chi, K. Fizazi, K. Herrmann, K. Rahbar, et al. Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer. New England J. Med. 385(12):1091\u20131103, 2021.","journal-title":"New England J. Med."},{"issue":"8","key":"4282_CR64","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/adhm.201300023","volume":"2","author":"G Gon\u00e7alves","year":"2013","unstructured":"Gon\u00e7alves, G., M. Vila, M. T. Portol\u00e9s, M. Vallet-Regi, J. Gracio, and P. A. A. Marques. Nano-graphene oxide: a potential multifunctional platform for cancer therapy. Adv. Healthcare Mater. 2(8):1072\u20131090, 2013.","journal-title":"Adv. Healthcare Mater."},{"key":"4282_CR65","first-page":"251596","volume":"66","author":"N Zaid","year":"2025","unstructured":"Zaid, N., G. Agasthya, A. Akhavanallaf, R. Boellaard, J. Brosch-lenz, G. Currie, et al. Image-based pharmacokinetic modeling and dosimetry: a paradigm for verification, validation and uncertainty quantification in computational nuclear oncology. Soc. Nuclear Med. 66:251596, 2025.","journal-title":"Soc. Nuclear Med."},{"issue":"2","key":"4282_CR66","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/0026-2862(90)90023-K","volume":"40","author":"LT Baxter","year":"1990","unstructured":"Baxter, L. T., and R. K. Jain. Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics. Microvasc. Res. 40(2):246\u2013263, 1990.","journal-title":"Microvasc. Res."},{"key":"4282_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172276","volume":"12","author":"W Zhan","year":"2017","unstructured":"Zhan, W., W. Gedroyc, and X. Xu. Spatiotemporal distribution modeling of PET tracer uptake in solid tumors. PLoS One.12:e0172276, 2017.","journal-title":"PLoS One."},{"key":"4282_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2020.105606","volume":"196","author":"R Rahpeima","year":"2020","unstructured":"Rahpeima, R., M. Soltani, and F. M. Kashkooli. Numerical study of microwave induced thermoacoustic imaging for initial detection of cancer of breast on anatomically realistic breast phantom. Comput. Methods Prog. Biomed.196:105606, 2020.","journal-title":"Comput. Methods Prog. Biomed."},{"issue":"10","key":"4282_CR69","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2217\/nnm-2021-0126","volume":"17","author":"FM Kashkooli","year":"2022","unstructured":"Kashkooli, F. M., M. Rezaeian, and M. Soltani. Drug delivery through nanoparticles in solid tumors: a mechanistic understanding. Nanomedicine. 17(10):695\u2013716, 2022.","journal-title":"Nanomedicine."},{"issue":"1","key":"4282_CR70","doi-asserted-by":"publisher","first-page":"21475","DOI":"10.1038\/s41598-021-00989-x","volume":"11","author":"F Moradi Kashkooli","year":"2021","unstructured":"Moradi Kashkooli, F., and M. Soltani. Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach. Sci. Rep. 11(1):21475, 2021.","journal-title":"Sci. Rep."},{"issue":"6","key":"4282_CR71","doi-asserted-by":"publisher","first-page":"e67025","DOI":"10.1371\/journal.pone.0067025","volume":"8","author":"M Soltani","year":"2013","unstructured":"Soltani, M., and P. Chen. Numerical modeling of interstitial fluid flow coupled with blood flow through a remodeled solid tumor microvascular network. PloS One. 8(6):e67025, 2013.","journal-title":"PloS One."},{"key":"4282_CR72","unstructured":"Soltani, M. Numerical modeling of drug delivery to solid tumor microvasculature. 2013."},{"key":"4282_CR73","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1118\/1.4923912","volume":"42","author":"M Soltani","year":"2015","unstructured":"Soltani, M., H. Bazmara, M. Sefidgar, R. Subramaniam, and A. Rahmim. SU-D-201-04: study on the impact of tumor shape and size on drug delivery to pancreatic tumors. Med. Phys. 42:3220, 2015.","journal-title":"Med. Phys."},{"issue":"3","key":"4282_CR74","first-page":"687","volume":"54","author":"M Rezaeian","year":"2022","unstructured":"Rezaeian, M., and M. Soltani. Computational modeling of intraperitoneal drug delivery for the treatment of peritoneal carcinomatosis. Amirkabir J. Mech. Eng. 54(3):687\u2013702, 2022.","journal-title":"Amirkabir J. Mech. Eng."},{"key":"4282_CR75","unstructured":"Curry FR, Michel CF, Renkin EM, editors. Mechanics and thermodynamics of transcapillary exchange. 1984."},{"issue":"2","key":"4282_CR76","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/pharmaceutics14020324","volume":"14","author":"M Rezaeian","year":"2022","unstructured":"Rezaeian, M., M. Soltani, A. Naseri Karimvand, and K. Raahemifar. Mathematical modeling of targeted drug delivery using magnetic nanoparticles during intraperitoneal chemotherapy. Pharmaceutics. 14(2):324, 2022.","journal-title":"Pharmaceutics."},{"issue":"1","key":"4282_CR77","doi-asserted-by":"publisher","first-page":"19350","DOI":"10.1038\/s41598-021-98638-w","volume":"11","author":"M Soltani","year":"2021","unstructured":"Soltani, M., M. Souri, and Kashkooli F. Moradi. Effects of hypoxia and nanocarrier size on pH-responsive nano-delivery system to solid tumors. Sci. Rep. 11(1):19350, 2021.","journal-title":"Sci. Rep."},{"issue":"14","key":"4282_CR78","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.3390\/cancers13143429","volume":"13","author":"G Birindelli","year":"2021","unstructured":"Birindelli, G., M. Drobnjakovic, V. Morath, K. Steiger, C. D\u2019Alessandria, E. Gourni, et al. Is hypoxia a factor influencing PSMA-directed radioligand therapy?\u2014An in silico study on the role of chronic hypoxia in prostate cancer. Cancers. 13(14):3429, 2021.","journal-title":"Cancers."},{"key":"4282_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2020.101989","volume":"60","author":"FM Kashkooli","year":"2020","unstructured":"Kashkooli, F. M., M. Soltani, M. Rezaeian, C. Meaney, M.-H. Hamedi, and M. Kohandel. Effect of vascular normalization on drug delivery to different stages of tumor progression: in-silico analysis. J. Drug Deliv. Sci. Technol.60:101989, 2020.","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"1","key":"4282_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/10739689709148314","volume":"4","author":"RK Jain","year":"1997","unstructured":"Jain, R. K. Delivery of molecular and cellular medicine to solid tumors. Microcirculation. 4(1):1\u201323, 1997.","journal-title":"Microcirculation."},{"issue":"10","key":"4282_CR81","first-page":"2814","volume":"34","author":"EA Swabb","year":"1974","unstructured":"Swabb, E. A., J. Wei, and P. M. Gullino. Diffusion and convection in normal and neoplastic tissues. Cancer Res. 34(10):2814\u20132822, 1974.","journal-title":"Cancer Res."},{"issue":"6","key":"4282_CR82","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5732\/cjc.011.10384","volume":"31","author":"Z-Y Wang","year":"2012","unstructured":"Wang, Z.-Y., Y. Xing, B. Liu, L. Lu, X. Huang, C.-Y. Ge, et al. Protective antitumor immunity induced by tumor cell lysates conjugated with diphtheria toxin and adjuvant epitope in mouse breast tumor models. Chinese J. Cancer. 31(6):295, 2012.","journal-title":"Chinese J. Cancer."},{"issue":"10","key":"4282_CR83","first-page":"2641","volume":"48","author":"RK Jain","year":"1988","unstructured":"Jain, R. K. Determinants of tumor blood flow: a review. Cancer Res. 48(10):2641\u20132658, 1988.","journal-title":"Cancer Res."},{"issue":"9","key":"4282_CR84","doi-asserted-by":"publisher","first-page":"3643","DOI":"10.1158\/0008-5472.CAN-04-1668","volume":"65","author":"PE Huber","year":"2005","unstructured":"Huber, P. E., M. Bischof, J. Jenne, S. Heiland, P. Peschke, R. Saffrich, et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res. 65(9):3643\u20133655, 2005.","journal-title":"Cancer Res."},{"key":"4282_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2023.100158","volume":"18","author":"S Rajput","year":"2023","unstructured":"Rajput, S., P. K. Sharma, and R. Malviya. Fluid mechanics in circulating tumour cells: role in metastasis and treatment strategies. Med. Drug Discov.18:100158, 2023.","journal-title":"Med. Drug Discov."},{"issue":"1","key":"4282_CR86","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jtbi.2011.02.017","volume":"279","author":"Y Cai","year":"2011","unstructured":"Cai, Y., S. Xu, J. Wu, and Q. Long. Coupled modelling of tumour angiogenesis, tumour growth and blood perfusion. J. Theoretical Biol. 279(1):90\u2013101, 2011.","journal-title":"J. Theoretical Biol."},{"issue":"8","key":"4282_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070395","volume":"8","author":"M Welter","year":"2013","unstructured":"Welter, M., and H. Rieger. Interstitial fluid flow and drug delivery in vascularized tumors: a computational model. PloS One.8(8):e70395, 2013.","journal-title":"PloS One."},{"key":"4282_CR88","first-page":"54226","volume":"114","author":"S Stapleton","year":"2016","unstructured":"Stapleton, S., D. Mirmilshteyn, J. Zheng, C. Allen, and D. A. Jaffray. Spatial measurements of perfusion, interstitial fluid pressure and liposomes accumulation in solid tumors. J. Vis. Exp.: JoVE. 114:54226, 2016.","journal-title":"J. Vis. Exp.: JoVE."},{"issue":"15","key":"4282_CR89","first-page":"4478","volume":"50","author":"Y Boucher","year":"1990","unstructured":"Boucher, Y., L. T. Baxter, and R. K. Jain. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 50(15):4478\u20134484, 1990.","journal-title":"Cancer Res."},{"issue":"8","key":"4282_CR90","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3390\/pharmaceutics16081009","volume":"16","author":"A Martino","year":"2024","unstructured":"Martino, A., R. Terracciano, B. Mili\u0107evi\u0107, M. Milo\u0161evi\u0107, V. Simi\u0107, B. C. Fallon, et al. An insight into perfusion anisotropy within solid murine lung cancer tumors. Pharmaceutics. 16(8):1009, 2024.","journal-title":"Pharmaceutics."},{"issue":"1","key":"4282_CR91","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1080\/10717544.2019.1660435","volume":"26","author":"M Rezaeian","year":"2019","unstructured":"Rezaeian, M., A. Sedaghatkish, and M. Soltani. Numerical modeling of high-intensity focused ultrasound-mediated intraperitoneal delivery of thermosensitive liposomal doxorubicin for cancer chemotherapy. Drug Deliv. 26(1):898\u2013917, 2019.","journal-title":"Drug Deliv."},{"issue":"3","key":"4282_CR92","first-page":"219","volume":"40","author":"A \u00d6rbom","year":"2025","unstructured":"\u00d6rbom, A., J. Strand, M. Altai, W. Zedan, A. Kristiansson, J. Ceder, et al. Intratumoral distribution of [177Lu] Lu-PSMA-617 over time and in relation to diagnostic tracers in animal models of prostate cancer. Cancer Biother. Radiopharm. 40(3):219\u2013227, 2025.","journal-title":"Cancer Biother. Radiopharm."},{"key":"4282_CR93","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1021\/acs.jmedchem.4c02329","volume":"68","author":"B Yang","year":"2025","unstructured":"Yang, B., C. Shan, X. Lv, X. Song, D. Zeng, R. An, et al. 177Lu-labeled heterodimeric agent with high stability targeting neovascularization for tumor radioligand therapy. J. Med. Chem. 68:3146\u20133156, 2025.","journal-title":"J. Med. Chem."},{"issue":"8","key":"4282_CR94","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00259-023-06169-5","volume":"50","author":"T Yang","year":"2023","unstructured":"Yang, T., L. Peng, J. Qiu, X. He, D. Zhang, R. Wu, et al. A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy. Eur. J. Nuclear Med. Mol. Imaging. 50(8):2331\u20132341, 2023.","journal-title":"Eur. J. Nuclear Med. Mol. Imaging"},{"issue":"9","key":"4282_CR95","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2967\/jnumed.123.265599","volume":"64","author":"Y Pang","year":"2023","unstructured":"Pang, Y., L. Zhao, J. Fang, J. Chen, L. Meng, L. Sun, et al. Development of FAPI tetramers to improve tumor uptake and efficacy of FAPI radioligand therapy. J. Nuclear Med. 64(9):1449\u20131455, 2023.","journal-title":"J. Nuclear Med."},{"issue":"1","key":"4282_CR96","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2967\/jnumed.120.245068","volume":"62","author":"LD Jim\u00e9nez-Franco","year":"2021","unstructured":"Jim\u00e9nez-Franco, L. D., G. Glatting, V. Prasad, W. A. Weber, A. J. Beer, and P. Kletting. Effect of tumor perfusion and receptor density on tumor control probability in 177Lu-DOTATATE therapy: an in silico analysis for standard and optimized treatment. J. Nuclear Med. 62(1):92\u201398, 2021.","journal-title":"J. Nuclear Med."},{"issue":"14","key":"4282_CR97","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.3390\/cancers16142515","volume":"16","author":"TG Reuvers","year":"2024","unstructured":"Reuvers, T. G., V. Grandia, R. M. Brandt, M. Arab, S. L. Maas, E. M. Bos, et al. Investigating the radiobiological response to peptide receptor radionuclide therapy using patient-derived meningioma spheroids. Cancers. 16(14):2515, 2024.","journal-title":"Cancers."},{"issue":"13","key":"4282_CR98","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1007\/s00259-022-05870-1","volume":"49","author":"CD van der Heide","year":"2022","unstructured":"van der Heide, C. D., and S. U. Dalm. Radionuclide imaging and therapy directed towards the tumor microenvironment: a multi-cancer approach for personalized medicine. Eur. J. Nuclear Med. Mol. Imaging. 49(13):4616\u20134641, 2022.","journal-title":"Eur. J. Nuclear Med. Mol. Imaging."},{"key":"4282_CR99","first-page":"1802","volume":"12","author":"J Wu","year":"2022","unstructured":"Wu, J. Selective enhancing blood flow in solid tumor tissue is the key for achieving satisfactory delivery and therapeutic outcome of nanodrugs via the EPR effect. MDPI. 12:1802, 2022.","journal-title":"MDPI"},{"issue":"6","key":"4282_CR100","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.13195","volume":"5","author":"GN Cattermole","year":"2017","unstructured":"Cattermole, G. N., P. M. Leung, G. Y. Ho, P. W. Lau, C. P. Chan, S. S. Chan, et al. The normal ranges of cardiovascular parameters measured using the ultrasonic cardiac output monitor. Physiological reports.5(6):e13195, 2017.","journal-title":"Physiological reports."},{"issue":"3","key":"4282_CR101","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41416-022-02109-6","volume":"128","author":"IF Tannock","year":"2023","unstructured":"Tannock, I. F., and Steel G. Gordon. Cell proliferation, drug distribution and therapeutic effects in relation to the vascular system of solid tumours. British J. Cancer. 128(3):413\u2013418, 2023.","journal-title":"British J. Cancer."},{"key":"4282_CR102","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fmolb.2019.00160","volume":"6","author":"E Henke","year":"2020","unstructured":"Henke, E., R. Nandigama, and S. Erg\u00fcn. Extracellular matrix in the tumor microenvironment and its impact on cancer therapy. Front. Mol. Biosci. 6:160, 2020.","journal-title":"Front. Mol. Biosci."},{"key":"4282_CR103","volume-title":"Study of Perfusion kinetics in human brain tumor using leaky tracer kinetic model of DCE-MRI data and CFD. Advanced computational methods in life system modeling and simulation","author":"A Bhandari","year":"2017","unstructured":"Bhandari, A., A. Bansal, A. Singh, and N. Sinha. Study of Perfusion kinetics in human brain tumor using leaky tracer kinetic model of DCE-MRI data and CFD. Advanced computational methods in life system modeling and simulation. Singapore: Springer Singapore, 2017."}],"container-title":["Annals of Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10439-026-04282-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10439-026-04282-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10439-026-04282-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T16:01:57Z","timestamp":1784476917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10439-026-04282-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,19]]},"references-count":103,"alternative-id":["4282"],"URL":"https:\/\/doi.org\/10.1007\/s10439-026-04282-8","relation":{},"ISSN":["0090-6964","1573-9686"],"issn-type":[{"value":"0090-6964","type":"print"},{"value":"1573-9686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,19]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human or animal subjects were involved in this study; therefore, no clinical trial registration is required.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human participants; thus, this section is not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}